乳腺癌亚型对放疗反应及潜在放疗敏感性的影响

放射治疗（ RT）对于乳腺癌至关重要，有超过50％的患者在治疗疾病的过程中接受RT，相当于全世界每年有500000名患者接受RT，不幸的是，并不是所有的病人均能获益，部分乳腺癌患者出现了局部复发及远处转移，因此个体化放射治疗将会是一个新局面，对于放疗不敏感的肿瘤给予更高的治疗剂量，而对于放疗无效的疾病避免了不必要的损伤，更具选择性的治疗将节约卫生服务资源，减轻放射治疗机器的负担，降低癌症治疗的经济成本，但目前还没有完善的预测放射治疗的生物标志物，本文将回顾性分析探讨乳腺癌分子亚型是否可以成功预测放射治疗的有效性。

The influences of breast cancer subtypes on reactivity and radiosensitisvity of radiotherapy

Radiotherapy(RT)is of importance in the management of breast cancer.Over 50% of patients receive RT at some time during the treatment of their disease,equating to over 500 000 patients worldwide receiving RT each year.Unfortunately,not all the patients derive from benefit and some breast cancers are resistant to treat-ment,as evidenced by distant metastatic spread and local recurrence.Prediction of individual responses to RT may allow a stratified approach to this treatment permitting those patients with radio-resistant tumours to receive higher doses of RT.Also,for those patients unlikely to respond at all,it would prevent from harmful side effects occurring for no therapeutic gain.More selective targeting would better direct National Health Service resources,ease the bur-den on heavily used treatment RT machines and reduce the economic cost of cancer treatment.Unfortunately,there are no robust and validated biomarkers for predicting RT outcome.We review the available literatures to determine whether classification of breast cancers according to their molecular subtypes may be used to predict successful re-sponse to increase morbidity from RT.